Redeye: IDL Biotech - Good growth prospects

Redeye raise our base case for IDL on the back of strong Q4’19 performance. Sales volumes are developing favorably and the company delivered black figures from its operations in the quarter. We view the future outlook as promising with continued good growth prospects and see several changes in market dynamics in IDL’s favor. We believe there is some further upside in the stock despite the strong recent rally, as investors are starting to buy into the long-term story.

Read more and download the research update: http://bit.ly/2SVyaaL

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/